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http://dx.doi.org/10.1016/j.jmii.2012Background: The incidence of candidemia varied between hospitals and different study
periods. Few, if any, studies provide the reasons. This hospital-based population study aimed
to describe and compare the patient population hospitalized in 2002 and 2010 and determine
the disease-specific incidences of candidemia and evaluate the impact of time to initiate anti-
fungal therapy on 30-day mortality.
Patients and methods: All patients hospitalized at a 2300-bed teaching hospital in Taiwan in
2002 and 2010 were analyzed for the distribution of age, sex, and type of underlying diseases
(maximum of six diagnoses). All patients with blood isolates that were collected in 2002 and
2010 and yielded Candida species were included for analysis of the demographic and clinical
characteristics, distribution of Candida species, length of hospital stay before candidemia,
stay in the intensive care units at onset of candidemia, time of initiating systemic antifungal
agent, antifungal regimen, and 30-day crude mortality.
Results: In 2010, the hospitalized patients were older (p < 0.001), had a higher Charlson Co-
morbidity Index (p < 0.001), and more underlying disease/status, including chronic pulmonaryof Internal Medicine, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei 10016,
il.com (Y.-C. Chen).
an Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
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96 P.-Y. Chen et al.Table 1 Characteristics of patie
Parameters
Number of acute care beds
Total number of admissions
Total number of patient-days
Age, y
Sex, male (%)
Charlson Comorbidity Index
Underlying disease/status, n (%)
Congestive heart failure
Cerebrovascular diseases
Chronic pulmonary diseases
Connective tissue diseases
Moderate-to-severe liver diseas
Moderate-to-severe renal disea
Diabetes mellitus without end o
Diabetes mellitus with end orga
Any tumora
Lymphoma
Leukemia
Gastrointestinal malignancyb
Metastatic solid tumor
Acquired immunodeficiency syn
Neutropenia
Solid organ transplantation (kid
Hematopoietic stem cell transp
Incidence density of candidemia (
a Any tumor is defined as any solid
b Gastrointestinal malignancy indi
intestines, and rectum.diseases, moderate-to-severe renal diseases, leukemia, lymphoma, and gastrointestinal malig-
nancies (p < 0.001) than those seen in 2002. Multivariate analysis identified the following host
factors were associated with the occurrence of candidemia in 2010: neonate (adjust odds ratio
[OR], 3.67), 45e64 year (OR, 2.18) and the elderly (OR 2.64), compared with young adult (20
e44 year); patients with moderate-to-severe renal diseases (OR, 8.08), leukemia (OR, 4.58)
and lymphoma (OR 3.98) and gastrointestinal malignancies (OR 2.80). The incidence density
of candidemia was 0.34 and 0.41 per 1000 patient-days in 2002 and 2010, respectively
(p Z 0.04). The majority of characteristics of patients with candidemia and disease-specific
incidences of candidemia did not differ between 2002 and 2010. Despite more patients in
2010 receiving antifungal therapy on the same day or 1 day after onset (27.5% vs. 41.2%,
respectively, p Z 0.002), the 30-day mortality remained high (45.9% in 2002 and 44.4% in
2010). Moreover, time to initiate antifungal therapy had no impact on 30-day mortality.
Conclusion: This hospital-based population study demonstrated that the incidence density of
candidemia was high and increased in 2010 compared with 2002, which was at least in part
due to the increase in the proportion of patients at a higher risk of candidemia. Although anti-
fungal therapy was initiated earlier in 2010, the 30-day mortality remained high.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Candida species are important pathogens causing
healthcare-associated infections and are associated with
high mortality, excess lengths of hospital stay, and medicalnts hospitalized at National Ta
es
ses
rgan damage
n damage
drome
ney, liver, heart, pancreas)
lantation
per 1000 patient-days)
malignancy excluding gastrointest
cates malignancies involving anycosts.1,2 A nation-wide surveillance data in Taiwan showed
that Candida species was the leading pathogens of
healthcare-associated infections in the intensive care
units (ICUs) of the medical centers and ranked second in
regional hospitals in 2010.3 The incidence of bloodstreamiwan University Hospital in 2002 and 2010
2002 2010 p value
2200 2300 d
66,763 79,710 d
632,318 691,692 d
47.3  23.6 51.2  22.9 <0.001
34,514 (54.58) 39,669 (57.35) <0.001
2.10  3.45 3.18  4.33 <0.001
1264 (18.93) 2595 (32.56) <0.001
3230 (48.38) 3682 (46.19) 0.04
2629 (39.38) 3372 (42.30) 0.005
828 (12.40) 2002 (25.12) <0.001
4076 (61.05) 3302 (41.43) <0.001
3568 (53.44) 3063 (38.43) <0.001
5447 (81.59) 10,530 (132.10) <0.001
918 (13.75) 1177 (14.77) 0.10
13,330 (199.66) 26,312 (330.10) <0.001
865 (12.96) 1776 (22.28) <0.001
1186 (17.76) 1779 (22.32) <0.001
1250 (18.72) 3377 (42.37) <0.001
4451 (66.67) 10,090 (126.58) <0.001
260 (3.89) 346 (4.34) 0.19
909 (13.62) 1231 (15.44) 0.004
392 (5.87) 662 (8.31) <0.001
29 (0.43) 106 (1.00) <0.001
218 (0.34) 286 (0.41) 0.04
inal malignancy, metastatic malignancy, leukemia and lymphoma.
part of the following organs: esophagus, stomach, small or large
Figure 1. Distribution of patients hospitalized at the
National Taiwan University Hospital in 2002 and 2010 by (A) age
group; and (B) Charlson Comorbidity Index. The proportions in
each age group or Charlson Comorbidity Index changed signif-
icantly (p < 0.001) as compared with those in 2002 and in 2010.
Epidemiology and Tx of candidemia 97infections with fungi (especially Candida species) has
increased substantially during recent decades.4e7 The
potential reasons include increase in patient population at
risk, and more extensive use of invasive procedures and
devices, broad-spectrum antimicrobial agents, advanced
life-support, and aggressive chemotherapy. The incidence
of candidemia varies between countries, patient pop-
ulations, and study periods.4e7 The incidence of candide-
mia in a multicenter study of healthcare-associated
bloodstream infection in Taiwan varied widely between
hospitals, and the highest incidence was observed in
a cancer center.7
In a hospital-wide surveillance study we observed an
average of 15.0% increase annually in incidence of
healthcare-associated bloodstream infection during 1981
and 2007,6 and Candida species have become the leading
healthcare-associated bloodstream pathogens since 1993.8
A prospective observational study during 1994 and 1995
showed high incidences of candidemia in surgical and
medical intensive care units and hemato-oncology units
(9.4, 6.3 and 2.4 per 1000 discharges, respectively), and no
antifungal therapy was an independent factor associated
with mortality.9 Since then, we adopted empirical anti-
fungal therapy for high-risk patients using either ampho-
tericin B or fluconazole.10
In a recent study, we observed a significant increase of
hospitalized patients with neoplasms from 22.0% during
January 1999 and March 2004 to 31.7% during April 2004 and
December 2007.11 Therefore, we retrospectively analyzed
the hospital-wide prospective surveillance data at this
2300-bed teaching hospital in Taiwan and aimed to describe
and compare the patient population hospitalized in 2002
and 2010 and determine the disease-specific incidences of
candidemia, as well as evaluate the impact of time to
initiate antifungal therapy on 30-day mortality.
Patients and methods
Hospital setting and infection control surveillance
program
National Taiwan University Hospital (NTUH) is a 2300-bed
major teaching hospital in Taiwan that provides both
primary and tertiary medical care. Prospective, hospital-
wide on-site surveillance of Healthcare-associated infec-
tions (HCAIs) had begun since 1981, and it was conducted
by weekly visits of full-time infection control nurses to all
patient units. The clinical and microbiologic data of all
hospitalized patients were reviewed, healthcare-
associated infections were defined according to the defi-
nitions provided by the U.S. Centers for Disease Control and
Prevention,12,13 and relevant information were collected.6
There was no cluster of Candida colonization or infec-
tion documented during the study period. Besides,
a previous active microbial surveillance study conducted
during 1996-1997 when the incidence of invasive candidiasis
increased rapidly at NTUH showed that Candida coloniza-
tion was common in adult patients stayed in the intensive
care units (ICUs).14 In addition, molecular epidemiologic
study based on pulse-field gel electrophoresis findings did
not identify cross-transmission between these patients.14Data collection or sources
All patients hospitalized at NTUH in 2002 and 2010 were
analyzed for the distribution of age, sex, type of underlying
diseases, and source of patients (from outpatient clinics,
emergence services, or transfer from other hospitals).
Underlying diseases, comprising a maximum of six diseases,
were recorded and classified according to International
Classification of Diseases, 9th Revision, Clinical Modification
(ICD-9-CM) codes, which were coded by Medical Information
Management personnel when patients were discharged from
the hospital.
All patientswithblood isolateswhichwerecollected in2002
and 2010 and yielded Candida spp. were included for analysis
of the demographic and clinical characteristics, distribution of
Candida species, length of hospital stay before and after onset
of candidemia, ICU stay at the onset of candidemia, use of
antifungal agent, time of initiating systemic antifungal agent,
antifungal regimen,and30-day crudemortality and in-hospital
mortality.Wedidnot recordthe therapeutic factorsother than
antimicrobial agents (such as parenteral nutrition, indwelling
central lines) anddelayedcomplicationsafterdischargedue to
candidemia. The laboratory methods for blood culture,
98 P.-Y. Chen et al.Candida spp. identification and antimicrobial susceptibility
were described previously.15,16
Antifungal strategy
We adopted empirical antifungal therapy for high-risk
patients using either amphotericin B or fluconazole13 as
a series of studies showed clinical isolates of Candida spp.
collected at NTUH remained highly susceptible to flucona-
zole and amphotericin B.10,17,18 Besides, Golan et al
demonstrated that empirical fluconazole therapy was the
most cost-effective strategy for ICU patients with high risks
for candidemia if fluconazole resistance rate was low.19
Antifungal prophylaxis was limited to allogeneic hemato-
poietic stem cell transplant recipients using fluconazole 19
or micafungin (since 2008).
Definitions
The severity of underlying diseases, comprising a maximum
of six diseases, was scored using the Charlson ComorbidityTable 2 Risk factors of patients who developed candidemia in
Parameters Univariate anal
Odds ratio 95% confidence
Lower Upp
Age
0e12 mo 2.54 1.04 6.1
1e19 y 1.08 0.54 2.1
20e44 y (as reference)
45e64 y 2.65 1.73 4.0
65 y 3.70 2.43 5.6
Sex, male 1.48 1.17 1.8
Charlson Comorbidity Index
0e1 (as reference)
2 2.57 1.68 3.9
3 3.94 2.49 6.2
4 6.62 4.63 9.4
Underlying diseases/status
Congestive heart failure 2.24 1.42 3.5
Cerebrovascular diseases 1.39 0.86 2.2
Chronic pulmonary diseases 2.27 1.52 3.4
Connective tissue diseases 1.12 0.55 2.2
Moderate-to-severe liver diseases 1.37 0.83 2.2
Moderate-to-severe renal diseases 8.76 6.70 11.4
Diabetes mellitus without
end organ damage
1.46 1.08 1.9
Diabetes mellitus with
end organ damage
0.95 0.35 2.5
Any tumor 1.16 0.91 1.4
Lymphoma 3.33 2.11 5.2
Leukemia 3.68 2.38 5.7
Gastrointestinal malignancy 3.93 2.83 5.4
Metastatic solid tumor 2.51 1.93 3.2
Neutropenia 3.06 1.75 5.3
Acquired immunodeficiency
syndrome
2.44 0.78 7.6
Solid organ transplant (kidney,
liver, heart, pancreas)
1.70 0.63 4.5Index.20 Candida colonization was defined as any Candida
isolated from any decision-driven clinical specimens
collected from the patients in the preceding 1 month of
candidemia. The timing to initiate antifungal therapy was
determined as the date to initiate antifungal agents
following the date when the first Candida-positive blood
sample for culture was drawn (Day 0). We segregated these
times as being on the same calendar day, 1 day later, 2 days
later, 3 days or more days later. No treatment was defined
as no systemic antifungal agents used during hospitalization
after the onset of candidemia. Breakthrough candidemia
indicated the patients had been on systemic antifungal
agents at the time when the first Candida-positive blood
sample for culture was drawn.
Statistical analysis
The difference in patient population and patients with
candidemia during the two study periods was examined
using Student’s t-test (continuous variables) and a chi-
squared test (categorical variables). The incidences of2010 by characteristics
ysis Multivariate analysis
interval p value Odds ratio 95% confidence interval p value
er Lower Upper
7 0.04 3.67 1.50 8.97 0.004
4 0.82 1.07 0.54 2.13 0.85
7 <0.001 2.18 1.42 3.30 <0.001
4 <0.001 2.64 1.72 4.06 <0.001
8 0.001
2 <0.001
1 <0.001
7 <0.001
4 0.001
4 0.18
1 <0.001 1.90 1.25 2.89 0.003
6 0.76
8 0.22
6 <0.001 8.08 6.11 10.67 <0.001
8 0.01
5 0.92
8 0.23
5 <0.001 3.98 2.49 6.35 <0.001
1 <0.001 4.58 2.90 7.23 <0.001
6 <0.001 2.80 1.93 4.05 <0.001
6 <0.001 2.32 1.72 3.14 <0.001
5 <0.001
6 0.12
7 0.29
Epidemiology and Tx of candidemia 99patients with candidemia by age group, Charlson Comor-
bidity Index, and underlying diseases were compared by
Poisson regression analyses.6 As regards to the risk factors
of candidemia, the univariate analyses were undertaken
using logistic regression. All variables significant at p < 0.05
in univariate analyses were considered as possible predictor
variables for the multivariable analyses, which was per-
formed by stepwise logistic regression. However, Charlson
Comorbitidy Index were not included in multivariate anal-
yses model because of colinearity with underlying diseases.
All statistical tests were considered two-tailed and were
significant at p <0.05. Statistical analyses were performed
using SAS 9.2 (SAS Institute, Cary, NC, USA).
Ethics statement
We followed the principles expressed in the Declaration of
Helsinki. This study was approved by the Institutional Ethics
Review Board of the National Taiwan University Hospital
(NTUH-201204058RIC).
Results
Patient population
The characteristics of patients hospitalized in 2002 and
2010 are summarized in Table 1. In 2010, age (p < 0.001),
Charlson Comorbidity Index (p < 0.001), and proportions ofTable 3 Comparison of characteristics of patients with candide
Parameters
Characteristics
Age, y
Sex, male, n (%)
Charlson Comorbidity Index
Prior Candida colonization within 1 month, n (%)
Prior antibiotics use within 1 month, n (%)
Prior antifungal agents use within 1 month, n (%)
Length of hospital stay before onset, d
Intensive care unit onset, n (%)
Disease-specific incidence (per 1000 admissions)
Congestive heart failure
Cerebrovascular diseases
Chronic pulmonary diseases
Connective tissue diseases
Moderate-to-severe liver diseases
Moderate-to-severe renal diseases
Diabetes mellitus without end organ damage
Diabetes mellitus with end organ damage
Any tumor
Lymphoma
Leukemia
Gastrointestinal malignancy
Metastatic solid tumor
Neutropenia
Acquired immunodeficiency syndrome
Solid organ transplantation (kidney, liver, heart, pancreas)
Hematopoietic stem cell transplantationmost underlying illness including chronic pulmonary
diseases, moderate-to-severe renal diseases, leukemia,
lymphoma and gastrointestinal malignancies significantly
increased (p < 0.001) compared with those in 2002. The
distribution of all hospitalized patients by age groups and
Charlson Comorbidity Index are shown in Fig. 1A and
Fig. 1B. The proportions in each age group or Charlson
Comorbidity Index changed significantly (p < 0.001) as
compared with those in 2002 and in 2010. In 2010 more than
one third of our patient populations had one or more
neoplasms.
Candida species distribution
There were 218 and 286 patients who had candidemia
during hospitalization in 2002 and 2010, respectively. The
distributions of Candida species were similar in these two
study periods (p Z 0.26). The most common species were
C. albicans (55.0% in 2002 vs. 53.2% in 2010), followed by C.
tropicalis (20.2% vs. 23.1%), C. glabrata (15.6% vs. 18.5%),
and C. parapsilosis (14.2% vs. 9.1%).
Risk factors of candidemia
The risk factors of candidemia among patients hospitalized
in 2010 are shown in Table 2. By univariate analysis, odds
ratios were higher in patients with extreme of age and
higher Charlson Comorbidity Index. Multivariate logisticmia and disease-specific incidence in 2002 and 2010
2002 (n Z 218) 2010 (n Z 286) p value
56.7  23.1 60.3  19.9 0.07
130 (59.6) 170 (59.4) 0.96
5.38  5.77 5.66  5.39 0.56
89 (40.8) 131 (45.8) 0.03
203 (93.1) 279 (97.6) 0.02
179 (82.1) 254 (88.8) 0.03
35. 6  54.4 25.8  29.8 0.02
66 (30.3) 87 (30.4) 0.25
10 (7.91) 20 (7.71) >0.99
22 (6.81) 18 (4.89) 0.37
22 (8.37) 26 (7.71) 0.89
2 (2.42) 8 (4.00) 0.81
20 (4.91) 16 (4.85) >0.99
54 (15.13) 73 (23.83) 0.01
21 (3.86) 52 (4.94) 0.41
3 (3.27) 4 (3.40) >0.99
52 (3.90) 104 (3.95) >0.99
11 (12.72) 20 (16.99) 0.56
17 (14.33) 22 (12.37) 0.76
36 (28.80) 42 (12.44) <0.001
53 (11.91) 76 (7.53) 0.01
11 (11.54) 13 (8.67) >0.99
3 (12.10) 3 (10.56) 0.89
2 (5.10) 4 (6.04) >0.99
0 (0.00) 0 (0.00) d
Figure 2. Incidences of candidemia (per 1000 admissions)
among patients hospitalized at National Taiwan University
Hospital in 2002 and 2010 by (A) age group and (B) Charlson
Comorbidity Index. There was no difference between these
two study years.
100 P.-Y. Chen et al.analysis, chronic pulmonary diseases, moderate-to-severe
renal disease, leukemia, lymphoma, gastrointestinal
malignancies and metastatic malignancies were significant
predictors of candidemia.
Characteristics of patients with candidemia
The demographic and clinical characteristics of the
patients with candidemia are shown in Table 3. The
proportions of prior antibiotics or antifungal use within one
month were high and both increased significantly in 2010
than those in 2002 (p Z 0.02 and p Z 0.03, respectively).
Length of hospital stay before onset of candidemia was
shorter by 10 days in 2010 (p Z 0.02).
The incidences of candidemia were 2.78 per 1000
admissions in 2002 and 2.88 per 1000 admissions in 2010
(p Z 0.71). The incidence density was 0.34 and 0.41 per
1000 patient-days (p Z 0.04), respectively. The incidences
of patients with candidemia per 1000 admissions in each
age group and Charlson Comorbidity Index are shown in
Fig. 2A and Fig. 2B. There was no difference between these
two study years. The disease-specific incidences of patients
with candidemia increased among patients with moderate-
to-severe renal diseases (p Z 0.01), but decreased among
those with gastrointestinal malignancy (p < 0.001), and
metastatic malignancy (p Z 0.01) in 2010 (Table 3).
Antifungal therapy and outcomes evaluation
As shown in Table 4,2 there was considerable variation in
the time to initiate antifungal therapy in 2002 and 2010,
and the most significant difference was more patients
received antifungal therapy one day later in 2010 (18.8% in
2002 vs. 30.4% in 2010, p Z 0.003). Antifungal therapy was
prescribed in 185 (84.9%) patients in 2002 and in 256 (89.5%)
patients in 2010. Choice of the first antifungal agent
showed uprising trend of fluconazole use (p Z 0.02) and
declining trend in amphotericin deoxycholate use
(pZ 0.03). In 2002, no echinocandins were used due to not
yet approval for candidemia in Taiwan. With regard to
outcome, the 30-day mortality was 45.9% in 2002 and 44.4%
in 2010 (p Z 0.74). The outcome was not better for those
treated earlier. The mortality was highest among those
received antifungal therapy one day later in 2002 (56.1%),
and among those with breakthrough candidemia in 2010
(52.2%).
Discussion
This hospital-based population study demonstrated that the
incidence density of candidemia increased in 2010
comparing to that in 2002. The reason for this trend, at
least in part, was due to the increase in the proportion of
patients at higher risk of candidemia (Table 1, Fig. 1)
including older patients, and patients with chronic pulmo-
nary diseases, leukemia, lymphoma, gastrointestinal
malignancies, and metastatic solid tumors (Table 2).
However, the majority of age group-specific and disease-
specific incidences of candidemia did not change signifi-
cantly (Table 3, Fig. 2). Although more patients in 2010
were treated earlier (Table 4), the 30-day mortality rateremained high and time to initiating antifungal therapy had
no impact on 30-day mortality.
In this study we showed the incidence density of can-
didemia up to 0.34 to 0.41 per 1,000 patient-days in 2002
and 2010, respectively, were higher than those in the
United States, Europe, and Australia,5,21e26 and were
comparative to those in Latin America27,28 and a recent
study in a medical center in Taiwan.29 A multicenter study
involving 11 teaching hospitals in Taiwan also showed
relatively high incidences of healthcare-associated candi-
demia compared with those worldwide.10 However, few if
any study providing data to explain this variation between
hospitals/countries/regions or time trends. In 2010 more
than one-third of our patient populations had one or more
neoplasms. Thus, composition of patient populations should
be taken into consideration when comparing disease
burden between hospitals or study periods.
Few population level studies provided age group-specific
or underlying disease/status-specific incidences of can-
didemia.30e33 With these data available, it is possible that
the disease burden can be adjusted and compared between
hospitals and study periods. In addition, we could predict
Table 4 Comparison of antifungal therapy and outcome for patients with candidemia in 2002 and 2010
2002 (n Z 218) 2010 (n Z 286) p value
Time to initiation of antifungal therapy
Same day 19 (8.72) 31 (10.84) 0.43
1 d later 41 (18.81) 87 (30.42) 0.003
2 d later 33 (15.14) 44 (15.38) 0.94
3 d later 38 (17.43) 35 (12.24) 0.10
No treatment 33 (15.14) 30 (10.49) 0.12
Breakthrough candidemia 54 (24.77) 59 (20.63) 0.27
First antifungal agent 185 (84.86) 256 (89.51) 0.12
Fluconazolea 162 (87.57) 242 (94.53) 0.009
Voriconazolea 0 (0.00) 1 (0.39) >0.99
Amphotericin Ba 18 (9.73) 5 (1.95) <0.001
Lipid formulation amphotericin Ba 1 (0.54) 0 (0.00) 0.42
Echinocandinsa 0 (0.00) 6 (2.34) 0.04
Combination therapya 4 (2.16) 2 (0.78) 0.24
30-day mortality 100 (45.87) 127 (44.41) 0.74
Same dayb 7/19 (36.84) 14/31 (45.16) 0.56
1 d laterb 23/41 (56.10) 35/87 (40.23) 0.09
2 d laterb 15/33 (45.45) 16/44 (36.36) 0.42
3 d laterb 12/38 (31.58) 11/35 (31.43) 0.99
No treatmentb 13/33 (39.39) 20/30 (66.67) 0.03
Breakthrough candidemiab 30/54 (55.56) 31/59 (52.54) 0.75
a Percentage by proportion of total patients receiving antifungal therapy.
b Mortality stratified by time to initiate antifungal therapy.
Epidemiology and Tx of candidemia 101time trends of incidences based on the composition of
patient populations in order to make decision regarding
antifungal strategy or to evaluate the impact of interven-
tion targeting for preventing infection.
The high-risk patient population for of candidemia
included neonate, the elderly, patients with moderate-to-
severe renal diseases, gastrointestinal malignancies, or
hematologic malignancies. These findings are consistent
with those described in review articles.34e36 In this study
there was no candidemia occurring among hematopoietic
stem cell transplantation recipients, which support the
success of antifungal prophylaxis before engraftment.
In this study we observed an unanticipated finding that
timing of initiating antifungal agent had no impact on 30-
day mortality. This finding was concordant to two recent
reports37,38 but differed from others.39,40 As to this
discrepancy, severity of illness, such as the Acute Physi-
ology and Chronic Health Evaluation (APACHE) II score,
should be taken into consideration. APACHE II score has
been a well-known independent predictor of mortality,
which might confound the impact of earlier initiating
antifungal therapy on mortality.41 Furthermore, more
patients in 2010 received antifungal therapy on one day
later, which might reflect the effect of continuous educa-
tion for our physicians to identify patients at risk and
implement empirical strategy. In addition, the outcome
was worse among patients without antifungal therapy in
2010 than those in 2002, probably because the majority of
them died before confirmation of the diagnosis.
Although this population study provides robust informa-
tion from epidemiological perspectives, there are several
limitations. First, this study did not provide information
regarding invasive procedure to adjust the disease-specificincidence. Second, the lack of APACHE II score in this study
might lead to more prudent interpretation of the impact of
timing of initiating antifungal therapy on mortality. Third,
the underlying diseases were retrieved from ICD-9 CM codes
of discharge diagnosis and limited to six. Thus, disease-
specific incidences might be underestimated or over-
estimated. Furthermore, this is a single-center study with
study periods limited to 2002 and 2010.
In conclusion, this hospital-based population study
demonstrated that the incidence density (and incidence) of
candidemia was high and increased in 2010 compared with
2002, which, at least in part, was due to the increase in the
proportion of patients at higher risk of candidemia. The 30-
day mortality remained high in 2010, which is even earlier
initiation of antifungal therapy.
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